V.K. Gadi, MD, PHD
Breast Mass
Workshop D
Disclosure: Dr. Gadi has no significant financial interest in any of the products or manufacturers mentioned.
The session will be case-based and require audience participation to succeed. The interactive session
will center on the following thematic areas:
1. Imaging. The goal is to understand how to work-up a breast mass and to know the guideline based
recommendation of preventative screening
2. Pathology: To review updates in diagnostic and molecular pathology in benign and cancerous breast
disease
3. Treatment: To review major updates in surgery, radiation therapy, and systemic therapy, and
prevention data.
4. Breast cancer risk assessment: To review high-risk circumstances and how to completely assess risk
with available modern data.
Outline:
1. Case 4 presentation – middle aged woman with dense breasts
a. Epidemiology of breast cancer and intrinsic breast cancer risk factors
b. Overview of different modalities of breast screening
i. Film versus digital mammograms
ii. Digital versus tomosynthesis mammography
iii. Supplemental ultrasound
iv. MRI screening
v. Other speculative techniques
2. Case presentation – young woman with BRCA mutation associated cancer
a. overview imaging and imaging guidelines for high-risk patients
b. overview pathology and molecular pathology of high-risk patients
c. overview role of prophylactic procedures for risk reduction
d. provide update on synthetic lethality and platinum agents in homologous recombination
defect breast cancer
e. reproduction considerations
f. update on duration and type of endocrine therapy
3. Case presentation – elderly patient with new screen detected mass
a. Discuss controversy of screening mammography in elderly patients
b. Provide updates on biology of low-risk breast cancers and t0 disease
c. Discuss prevention and treatment benefits of endocrine therapy
d. Overview harms of endocrine therapy
4. Case presentation – male breast cancer
a. Share epidemiology of male breast cancer
b. Management similarities and differences in male breast cancer compared to female breast
cancer
c. Genetics and male breast cancer
REFERENCES
1. Nelson HD, Tyne K, Naik A, et al.: Screening for breast cancer: an update for the U.S. Preventive
Services Task Force. Ann Intern Med 151 (10): 727-37, W237-42, 2009.
2. Rafferty EA, Park JM, Philpotts LE, Poplack SP, Sumkin JH, Halpern EF, Niklason LT. Assessing
radiologist performance using combined digital mammography and breast tomosynthesis compared
with digital mammography alone: results of a multicenter, multireader trial. Radiology. 2013
Jan;266(1):104-13.
3. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP
3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM,
Gabrielli G; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening
ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.
JAMA. 2012 Apr 4;307(13):1394-404.
4. Lehman CD1, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD,
Julian TB, DePeri ER, Bluemke DA, Schnall MD; ACRIN Trial 6667 Investigators Group. MRI evaluation of
the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007 Mar
29;356(13):1295-303.
5. Fong PC1, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A,
O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose)
polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34.
6. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada
GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle
JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G,
Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group.
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):43646.
7. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ,
Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D,
Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J,
Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators;
International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in
premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18.
8. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI,
Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophorectomy in women with a
BRCA1 or BRCA2 mutation.N Engl J Med. 2002 May 23;346(21):1609-15.
9. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A,
Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M,
Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F,
Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto
R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of
continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen
receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16.
10. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A,
Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E,
Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breastcancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23;364(25):2381-91
11. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL.
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for
early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793-802.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in
early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015 Jul
23 pii: S0140-6736(15)60908-4.
13. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of
denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin
Oncol. 2008 Oct 20;26(30):4875-82.
14. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL,
Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE,
Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230
Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J
Med. 2015 Mar 5;372(10):923-32.